Market Context — Why This Technology, Why Now

Aging populations and rising chronic disease prevalence are driving an urgent global demand for effective, safe, and affordable treatments. Healthcare systems are increasingly seeking drug repositioning strategies to mitigate the high costs and risks associated with de novo drug development. This technology aligns perfectly with these trends, offering a validated compound for a new indication, which could significantly reduce R&D timelines and provide a much-needed alternative for patients with limited existing treatment options.

Key Competitive Advantages
01

Leverages existing drug to reduce development time by ~3.5 years

02

Reduces side effect risk, suitable for long-term use

03

Addresses unmet needs with a new therapeutic option

Market Opportunity
Nasal and ENT Therapeutics
$350M globally (AI est.)
The increasing prevalence of chronic rhinosinusitis and limitations of existing treatments drive high demand for new options, particularly for refractory and severe cases.
Major pharmaceutical companies with ENT portfolios Biotech firms specializing in respiratory therapeutics Medical device companies developing nasal drug delivery systems
Metabolic Disease Co-Therapeutics
$1.5B–$3.5B globally (AI est.)
Statins are widely prescribed for hyperlipidemia, with established safety and efficacy. This offers high compatibility with existing medical infrastructure, lowering barriers to market entry.
Pharmaceutical companies with established statin franchises Generics manufacturers seeking new indications Healthcare providers focused on integrated chronic disease management
Drug Repositioning & Development
$15B–$20B globally (AI est.)
As new drug development costs and risks rise, repurposing existing drugs is gaining significant attention. This technology aligns with this trend, promising efficient development and early market introduction.
R&D-focused pharmaceutical companies Venture capital-backed biotech startups Contract research organizations (CROs) specializing in clinical trials
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects the use of statins as an active ingredient for preventing or treating chronic rhinosinusitis, covering three distinct claims. Its robustness is evidenced by overcoming two office actions during examination, with five prior art references cited, indicating a strong and stable right for licensees.

Competitive White Space

This patent focuses on statin compounds for chronic rhinosinusitis. White space exists in developing novel delivery systems for targeted sinus application or exploring combination therapies with non-statin anti-inflammatory agents.

Economic Impact
~$20M/year estimated healthcare cost reduction per country (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Assuming 100,000 chronic rhinosinusitis patients undergo surgery annually in Japan, with an average cost of $2,000 (AI est.) per surgery, the total annual surgical expenditure is ~$200M (AI est.). If this technology improves surgical avoidance by 10%, it could lead to an annual healthcare cost reduction of ~$20M (AI est.). Additional socio-economic benefits from improved patient quality of life are also expected.

Speed to Market
1× faster than in-house development
The accelerated market entry for this technology is attributed to statins already being approved as hyperlipidemia treatments, with extensive long-term safety data. This allows for the omission of many preclinical and toxicity studies typically required for novel compounds, streamlining the clinical trial phase and significantly reducing time to market. Leveraging existing manufacturing processes and supply chains is also a key advantage.
Competitive Positioning

X: Safety & Long-Term Suitability
Y: Fundamental Anti-Inflammatory Effect

Business Models & Applications
💊 Pharmaceutical Development & Sales
Develop, manufacture, and sell chronic rhinosinusitis treatment drugs based on this technology, maximizing revenue through domestic and international sales.
🤝 Licensing
Grant licenses for this patent to pharmaceutical companies or biotech ventures, generating royalty income and milestone payments while diversifying development risks.
🔬 Collaborative R&D
Collaborate with universities, research institutions, or other pharmaceutical companies to further elucidate statin's pharmacological mechanisms or expand its applicable indications.
Adjacent Application Opportunities
🩹 Inflammatory Diseases
Statin Treatment for Other Chronic Inflammatory Conditions
The anti-inflammatory properties of statins could be applied to various other chronic inflammatory diseases beyond chronic rhinosinusitis, such as rheumatoid arthritis or inflammatory bowel disease. Leveraging the insights from this technology to pivot towards developing new treatments for these conditions could expand business scope into a multi-billion dollar market.
👃 Respiratory Diseases
Prevention & Treatment of Asthma and COPD
Statins' anti-inflammatory effects may also be beneficial for respiratory conditions closely related to rhinosinusitis, such as asthma or chronic obstructive pulmonary disease (COPD). Expanding the application to the broader respiratory medicine sector could open new markets, potentially impacting millions of patients globally.
🧪 Functional Foods & Supplements
Functional Food Development for Nasal Health
Beyond pharmaceutical development, the active components or action mechanisms related to statins could be repurposed for functional foods or supplements aimed at maintaining nasal health or preventing inflammation. This could lead to an entry into the over-the-counter (OTC) market, a segment valued at over $100 billion annually.
Integration Roadmap — Estimated 42-Month Deployment
Preclinical & Formulation Study
Duration: 6 months
Further validate the pharmacological mechanism of this technology and evaluate optimal formulation and administration routes. Assess the applicability of existing statin formulations.
Clinical Trials (Phase I/II/III)
Duration: 24 months
Conduct efficient clinical trials (Phase I/II/III) due to statins being an approved active ingredient. Gather necessary data for regulatory approval by evaluating safety and efficacy.
Manufacturing, Regulatory Approval & Market Launch
Duration: 12 months
After clinical data compilation, submit for regulatory approval. Concurrently establish manufacturing systems and execute product launch and marketing strategies for market entry.
Technical Feasibility
This technology, using already approved statins as an active ingredient, is exceptionally easy to integrate into existing pharmaceutical development and manufacturing processes compared to novel compound development. Statin manufacturing infrastructure and quality control standards are well-established, eliminating the need for new compound synthesis or large-scale capital investment. This allows for maximum utilization of existing pharmaceutical manufacturing lines and supply chains, indicating very high technical feasibility and significant cost and time savings for adopting companies.
Success Scenario
If an adopting company commercializes this technology as a pharmaceutical product, it could become a new treatment option for patients suffering from chronic rhinosinusitis. Patients with limited efficacy from existing treatments may experience significant improvements in their quality of life, potentially increasing cases where surgery can be avoided. This could contribute to optimizing healthcare costs and establishing a competitive advantage in the market. Furthermore, the safety profile of statins suggests widespread adoption as a long-term preventive and therapeutic agent.
Patent Record
APPLICATION NO.
特願2020-170536
REGISTRATION NO.
7672675
FILING DATE
2020/10/08
GRANT DATE
2025/04/25
EXPIRATION DATE
2040/10/08
PATENT HOLDER
国立大学法人福井大学
Examination History
2023年06月06日
出願審査請求書
2024年06月11日
拒絶理由通知書
2024年08月06日
手続補正書（自発・内容）
2024年08月06日
意見書
2024年11月05日
拒絶理由通知書
2025年02月27日
意見書
2025年02月27日
手続補正書（自発・内容）
2025年04月08日
特許査定